New York A 3973: Relates to creating the NYS entrepreneurial training act of 2017

Status: ENACTING CLAUSE STRICKEN (as of 2018-04-30)

State: New York · Session: 2017-2018 · Bill: A 3973

Sponsors: SEPULVEDA

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
A03973 Summary:

BILL NOA03973A

&nbsp

SAME ASSAME AS S03485-A

&nbsp

SPONSORMcDonald

&nbsp

COSPNSRJacobson, Manktelow, Brown K, Otis

&nbsp

MLTSPNSR

&nbsp

Amd §§4903, 3242 & 4329, Ins L

&nbsp

Relates to prescription drug formulary coverage for interchangeable biologics and biosimilars.

Go to top A03973 Actions:

BILL NOA03973A

&nbsp

01/30/2025referred to insurance

06/02/2025amend and recommit to insurance

06/02/2025print number 3973a

06/08/2025reference changed to ways and means

06/09/2025reported referred to rules

01/07/2026referred to ways and means

05/05/2026reported 

05/07/2026advanced to third reading cal.450

Go to topA03973 Committee&nbspVotes:

Committee:WAYS AND MEANS Chair:Pretlow 
DATE:06/09/2025AYE/NAY:31/0 Action: Favorable refer to committee Rules PretlowAyeRaAye

GlickAyeFitzpatrickAye

ColtonAyeHawleyAye

CookAyeBlankenbushAye

BenedettoAyePalmesanoAye

WeprinAyeWalshAye

RamosAyeDeStefanoAye

BraunsteinAyeManktelowAye

McDonaldAyeSmullenAye

RozicAyeGiglioAye

DinowitzAye

MagnarelliAbsent

BronsonAye

DilanAye

SeawrightAye

HyndmanAbsent

WalkerExcused

Bichotte HermelAye

SimonAye

CruzAye

OtisAye

SolagesAye

HunterAye

EpsteinAye

SeptimoAbsent

Committee:WAYS AND MEANS Chair:Pretlow 
DATE:05/05/2026AYE/NAY:30/0 Action: Favorable PretlowAyePalmesanoAye

GlickAyeFitzpatrickExcused

ColtonAyeHawleyAye

CookExcusedBlankenbushAye

BenedettoAyeWalshAye

WeprinAyeDeStefanoAye

RamosAyeManktelowAye

BraunsteinAbsentSmullenAye

McDonaldAyeGiglioAye

RozicAyeSlaterAye

DinowitzAye

MagnarelliAye

BronsonAye

DilanAye

SeawrightExcused

HyndmanAye

WalkerAye

Bichotte HermelExcused

SimonAye

CruzAye

OtisAye

SolagesAye

HunterAye

SeptimoAye

HevesiAye

Go to topA03973 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topA03973 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 3973--A

 2025-2026 Regular Sessions

 IN ASSEMBLY

 January 30, 2025
 ___________

 Introduced by M. of A. McDONALD, JACOBSON, MANKTELOW, K. BROWN -- read
 once and referred to the Committee on Insurance -- committee
 discharged, bill amended, ordered reprinted as amended and recommitted
 to said committee

 AN ACT to amend the insurance law, in relation to prescription drug
 formulary coverage for interchangeable biologics and biosimilars

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Paragraph 4 of subsection (c-1) of section 4903 of the
 2 insurance law, as added by chapter 512 of the laws of 2016, is amended
 3 to read as follows:
 4 (4) The insured is stable on a prescription drug or drugs selected by
 5 their health care professional for the medical condition under consider-
 6 ation, provided that this shall not prevent a utilization review agent
 7 from [requiring an insured to try an AB-rated generic equivalent prior
 8 to providing coverage for the equivalent brand name prescription drug or
 9 drugs; or]:
 10 (i) requiring an insured to try an AB-rated generic equivalent or an
 11 interchangeable biological product prior to providing coverage for the
 12 equivalent brand name prescription drug or drugs, or
 13 (ii) requiring an insured to try a biosimilar prior to providing
 14 coverage for the brand name prescription reference product drug or
 15 drugs.
 16 § 2. Subparagraph (A) of paragraph 3 of subsection (c) of section 3242
 17 of the insurance law, as added by chapter 99 of the laws of 2022, is
 18 amended to read as follows:
 19 (A) An insurer with a formulary that includes two or more tiers of
 20 benefits providing for different deductibles, copayments or coinsurance
 21 applicable to prescription drugs in each tier may move a prescription
 22 drug to a tier with a larger deductible, copayment or coinsurance if an
 23 AB-rated generic equivalent [or], an interchangeable biological product,

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD03429-03-5

 A. 3973--A 2

 1 or biosimilar for such prescription drug is added to the formulary at
 2 the same time.
 3 § 3. Subparagraph (A) of paragraph 3 of subsection (c) of section
 4 4329 of the insurance law, as added by chapter 99 of the laws of 2022,
 5 is amended to rea

View New York A 3973 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.